NEW
YORK, Sept. 21, 2022 /PRNewswire/ -- The Gross
Law Firm issues the following notice to shareholders of Kiromic
BioPharma, Inc..
Shareholders who purchased shares of KRBP during the class
period listed are encouraged to contact the firm regarding possible
lead plaintiff appointment. Appointment as lead plaintiff is not
required to partake in any recovery.
CONTACT US HERE:
https://securitiesclasslaw.com/securities/kiromic-biopharma-inc-loss-submission-form/?id=31950&from=4
CLASS PERIOD: This lawsuit is on behalf of a class
consisting of persons and entities that purchased or otherwise
acquired: (a) Kiromic common stock issued in connection with the
Company's public offering that closed on July 2, 2021 and/or (b) Kiromic common stock
between June 25, 2021 and
August 13, 2021, both dates
inclusive.
ALLEGATIONS: The complaint alleges that the registration
statement and prospectus issued in connection with the Company's
public offering that closed on July 2,
2021 (the "Offering Documents") failed to disclose that the
Food and Drug Administration ("FDA") had, prior to the filing of
these documents, imposed a clinical hold on the Company's
Investigational New Drug ("IND") applications for its two new drug
candidates. Given that the offering closed on July 2, 2021, more than thirty (30) days after
the Company submitted the IND applications for its two
immunotherapy product candidates, investors were assured that no
clinical hold had been issued and clinical trials would
commence.
DEADLINE: October 4, 2022
Shareholders should not delay in registering for this class action.
Register your information here:
https://securitiesclasslaw.com/securities/kiromic-biopharma-inc-loss-submission-form/?id=31950&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a
shareholder who purchased shares of KRBP during the timeframe
listed above, you will be enrolled in a portfolio monitoring
software to provide you with status updates throughout the
lifecycle of the case. The deadline to seek to be a lead plaintiff
is October 4, 2022. There is no cost
or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is nationally
recognized class action law firm, and our mission is to protect the
rights of all investors who have suffered as a result of deceit,
fraud, and illegal business practices. The Gross Law Firm is
committed to ensuring that companies adhere to responsible business
practices and engage in good corporate citizenship. The firm seeks
recovery on behalf of investors who incurred losses when false
and/or misleading statements or the omission of material
information by a company lead to artificial inflation of the
company's stock. Attorney advertising. Prior results do not
guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original
content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-kiromic-biopharma-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-october-4-2022--nasdaq-krbp-301628898.html
SOURCE The Gross Law Firm